| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5698064 | Clinical Oncology | 2016 | 6 Pages |
Abstract
Lung cancer is the most common cancer diagnosed in the UK. Outcomes for patients with this disease remain poor and new strategies to treat this disease require investigation. One potential option is to combine novel agents with radiotherapy in clinical studies. Here we discuss some of the important issues to consider when combining novel agents with radiotherapy, together with potential solutions as discussed at a recent Clinical Translational Radiotherapy Group (CTRad) workshop.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
S. Harrow, G.G. Hanna, C. Faivre-Finn, F. McDonald, A.J. Chalmers,